Considerations on clinical use of T cell immunotherapy for cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 51, Issue 4, 2003, Pages 245-257

  Plautz, Gregory E ^a,b   Cohen, Peter A ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Dendritic cell; Immunotherapy; T lymphocyte; Tumor antigens

Indexed keywords

BCG VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT CYTOKINE; T LYMPHOCYTE RECEPTOR; TELOMERASE; TUMOR ANTIGEN; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; HETEROKARYON; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LYMPHOCYTE DEPLETION; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0042926832     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. AGARWALA S. S. and KIRKWOOD J. M. (1996): Interferons in melanoma. Curr. Opin. Oncol., 8, 167-174.
2. ALEXANDER J., FIKES J., HOFFMAN S., FRANKE E., SACCI J., APPELLA E., CHISARI F. V., GUIDOTTI L. G., CHESNUT R. W., LIVINGSTON B. and SETTE A. (1998): The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res., 18, 79-92.
3. ALEXANDER J., SIDNEY J., SOUTHWOOD S., RUPPERT J., OSEROFF C., MAEWAL A., SNOKE K., SERRA H. M., KUBO R. T. and SETTE A. (1994): Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1, 751-761.
4. ANDERSON G. R., BRENNER B. M., SWEDE H., CHEN N., HENRY W. M., CONROY J. M., KARPENKO M. J., ISSA J. P., BARTOS J. D., BRUNELLE J. K., JAHREIS G. P., KAHLENBERG M. S., BASIK M., SAIT S., RODRIGUEZ-BIGAS M. A., NOWAK N. J., PETRELLI N. J., SHOWS T. B. and STOLER D. L. (2001): Intrachromosomal genomic instability in human sporadic colorectal cancer measured by genome-wide allelotyping and inter-(simple sequence repeat) PCR. Cancer Res., 61, 8274-8283.
5. ATKINS M. B., ROBERTSON M. J., GORDON M., LOTZE M. T., DECOSTE M., DUBOIS J. S., RITZ J., SANDLER A. B., EDINGTON H. D., GARZONE P. D., MIER J. W., CANNING C. M., BATTIATO L., TAHARA H. and SHERMAN M. L. (1997): Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 3, 409-417.
6. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood, 97, 2923-2931.
7. + progenitor-derived dendritic cell vaccine. Cancer Res., 61, 6451-6458.
8. + tumor-infiltrating lymphocytes. J. Exp. Med., 173, 647-658.
9. BENNETT S. R., CARBONE F. R., KARAMALIS F., FLAVELL R. A., MILLER J. F. and HEATH W. R. (1998): Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 393, 478-480.
10. BUTTERFIELD L. H., RIBAS A., DISSETTE V. B., AMARNANI S. N., VU H. T., OSEGUERA D., WANG H. J., ELASHOFF R. M., MCBRIDE W. H., MUKHERJI B., COCHRAN A. J., GLASPY J. A. and ECONOMOU J. S. (2003): Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res., 9, 998-1008.
11. CHAN A. D. and MORTON D. L. (1998): Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin. Oncol., 25, 611-622.
12. CHANG A. E., ARUGA A., CAMERON M. J., SONDAK V. K., NORMOLLE D. P., FOX B. A. and SHU S. (1997): Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol., 15, 796-807.
13. CHANG A. E., REDMAN B. G., WHITFIELD J. R., NICKOLOFF B. J., BRAUN T. M., LEE P. P., GEIGER J. D. and MULE J. J. (2002): A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res., 8, 1021-1032.
14. CHILDS R., CHERNOFF A., CONTENTIN N., BAHCECI E., SCHRUMP D., LEITMAN S., READ E. J., TISDALE J., DUNBAR C., LINEHAN W. M., YOUNG N. S. and BARRETT A. J. (2000): Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med., 343, 750-758.
15. CHILDS R. W., CLAVE E., TISDALE J., PLANTE M., HENSEL N. and BARRETT J. (1999): Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J. Clin. Oncol., 17, 2044-2049.
16. COHEN P. A., PENG L., KJAERGAARD J., PLAUTZ G. E., FINKE J. H., KOSKI G. K., CZERNIECKI B. J. and SHU S. (2001): T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit. Rev. Immunol., 21, 215-248.
17. COULIE P. G., BRICHARD V., VAN PEL A., WOLFEL T., SCHNEIDER J., TRAVERSARI C., MATTEI S., DE PLAEN E., LURQUIN C., SZIKORA J.-P., RENAULD J.-C. and BOON T. (1994): A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180, 35-42.
18. DISIS M. L., BERNHARD H., SHIOTA F. M., HAND S. L., GRALOW J. R., HUSEBY E. S., GILLIS S. and CHEEVER M. A. (1996): Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood, 88, 202-210.
19. DISIS M. L., GRABSTEIN K. H., SLEATH P. R. and CHEEVER M. A. (1999): Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res., 5, 1289-1297.
20. DUDLEY M. E., WUNDERLICH J., NISHIMURA M. I., YU D., YANG J. C., TOPALIAN S. L., SCHWARTZENTRUBER D. J., HWU P., MARINCOLA F. M., SHERRY R., LEITMAN S. F. and ROSENBERG S. A. (2001): Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother., 24, 363-373.
21. DUDLEY M. E., WUNDERLICH J. R., ROBBINS P. F., YANG J. C., HWU P., SCHWARTZENTRUBER D. J., TOPALIAN S. L., SHERRY R., RESTIFO N. P., HUBICKI A. M., ROBINSON M. R., RAFFELD M., DURAY P., SEIPP C. A., ROGERS-FREEZER L., MORTON K. E., MAVROUKAKIS S. A., WHITE D. E. and ROSENBERG S. A. (2002): Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, 850-854.
22. DUDLEY M. E., WUNDERLICH J. R., YANG J. C., HWU P., SCHWARTZENTRUBER D. J., TOPALIAN S. L., SHERRY R. M., MARINCOLA F. M., LEITMAN S. F., SEIPP C. A., ROGERS-FREEZER L., MORTON K. E., NAHVI A., MAVROUKAKIS S. A., WHITE D. E. and ROSENBERG S. A. (2002): A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother., 25, 243-251.
23. DUNN G. P., BRUCE A. T., IKEDA H., OLD L. J. and SCHREIBER R. D. (2002): Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
24. + T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest., 110, 1813-1822.
25. FARAG S. S., FEHNIGER T. A., RUGGERI L., VELARDI A. and CALIGIURI M. A. (2002): Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood, 100, 1935-1947.
26. FONG L., HOU Y., RIVAS A., BENIKE C., YUEN A., FISHER G. A., DAVIS M. M. and ENGLEMAN E. G. (2001): Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA, 98, 8809-8814.
27. GABRILOVICH D. I., CORAK J., CIERNIK I. F., KAVANAUGH D. and CARBONE D. P. (1997): Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3, 483-490.
28. GALEA-LAURI J., DARLING D., MUFTI G., HARRISON P. and FARZANEH F. (2002): Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother., 51, 299-310.
29. GITLITZ B. J., HOFFMAN D. M., MOLDAWER N., BELLDEGRUN A. and FIGLIN R. A. (2001): Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J., 7, 112-120.
30. GNJATIC S., ATANACKOVIC D., MATSUO M., JAGER E., LEE S. Y., VALMORI D., CHEN Y. T., RITTER G., KNUTH A. and OLD L. J. (2003): Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J. Immunol., 170, 1191-1196.
31. GONG J., AVIGAN D., CHEN D., WU Z., KOIDO S., KASHIWABA M. and KUFE D. (2000): Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA, 97, 2715-2718.
32. GRAHAM S., BABAYAN R. K., LAMM D. L., SAWCZUK I., ROSS S. D., LAVIN P. T., OSBAND M. E. and KRANE R. J. (1993): The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin. Urol., 11, 27-34.
33. HAYASHI T., TANAKA H., TANAKA J., WANG R., AVERBOOK B. J., COHEN P. A. and SHU S. (2002): Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. Immunol., 104, 14-20.
34. HEISER A., COLEMAN D., DANNULL J., YANCEY D., MAURICE M. A., LALLAS C. D., DAHM P., NIEDZWIECKI D., GILBOA E. and VIEWEG J. (2002): Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest., 109, 409-417.
35. HEISER A., DAHM P., YANCEY D. R., MAURICE M. A., BOCZKOWSKI D., NAIR S. K., GILBOA E. and VIEWEG J. (2000): Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol., 164, 5508-5514.
36. HEISER A., MAURICE M. A., YANCEY D. R., COLEMAN D. M., DAHM P. and VIEWEG J. (2001): Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res., 61, 3388-3393.
37. HERNBERG M., PYRHONEN S. and MUHONEN T. (1999): Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J. Immunother., 22, 145-154.
38. HERSH E. M., METCH B. S., MUGGIA F. M., BROWN T. D., WHITEHEAD R. P., BUDD G. T., RINEHART J. J., CRAWFORD E. D., BONNET J. D. and BEHRENS B. C. (1991): Phase II studies of recombinant human tumor necrosis factor α in patients with malignant disease: a summary of the Southwest Oncology Group experience. J. Immunother., 10, 426-431.
39. HERSH E. M. and TAYLOR C. W. (1991): Immunotherapy by active immunization: use of nonspecific stimulants and immunomodulators. In DEVITA V. T., HELLMAN S. and ROSENBERG S. A. (eds.): Biologic theapy of cancer. J. B. Lippincott, Philadelphia, 613-626.
40. HOLMES L. M., LI J., STICCA R. P., WAGNER T. E. and WEI Y. (2001): A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J. Immunother., 24, 122-129.
41. HSUEH E. C., GUPTA R. K., QI K. and MORTON D. L. (1998): Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol., 16, 2913-2920.
42. HSUEH E. C., NATHANSON L., FOSHAG L. J., ESSNER R., NIZZE J. A., STERN S. L. and MORTON D. L. (1999): Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer, 85, 2160-2169.
43. HUANG A. Y. C., GOLUMBEK P., AHMADZADEH M., JAFFEE E., PARDOLL D. and LEVITSKY H. (1994): Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264, 961-965.
44. INOUE M., PLAUTZ G. E. and SHU S. (1996): Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res., 56, 4702-4708.
45. JAFFEE E. M., HRUBAN R. H., BIEDRZYCKI B., LAHERU D., SCHEPERS K., SAUTER P. R., GOEMANN M., COLEMAN J., GROCHOW L., DONEHOWER R. C., LILLEMOE K. D., O'REILLY S., ABRAMS R. A., PARDOLL D. M., CAMERON J. L. and YEO C. J. (2001): Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol., 19, 145-156.
46. KAGAMU H., TOUHALISKY J. E., PLAUTZ G. E., KRAUSS J. C. and SHU S. (1996): Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res., 56, 4338-4342.
47. KAWAKAMI Y., ELIYAHU S., DELGADO C. H., ROBBINS P. F., RIVOLTINI L., TOPALIAN S. L., MIKI T. and ROSENBERG S. A. (1994): Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91, 3515-3519.
48. KAWAKAMI Y., ELIYAHU S., DELGADO C. H., ROBBINS P. F., SAKAGUCHI K., APPELLA E., YANNELLI J. R., ADEMA G. J., MIKI T. and ROSENBERG S. A. (1994): Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91, 6458-6462.
49. KAWAKAMI Y., DANG N., WANG X., TUPESIS J., ROBBINS P. F., WANG R. F., WUNDERLICH J. R., YANNELLI J. R. and ROSENBERG S. A. (2000): Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother., 23, 17-27.
50. KEILHOLZ U., WEBER J., FINKE J. H., GABRILOVICH D. I., KAST W. M., DISIS M. L., KIRKWOOD J. M., SCHEIBENBOGEN C., SCHLOM J., MAINO V. C., LYERLY H. K., LEE P. P., STORKUS W., MARINCOLA F., WOROBEC A. and ATKINS M. B. (2002): Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother., 25, 97-138.
51. KHONG H. T. and RESTIFO N. P. (2002): Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol., 3, 999-1005.
52. KIKUCHI T., AKASAKI Y., IRIE M., HOMMA S., ABE T. and OHNO T. (2001): Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother., 50, 337-344.
53. KNUTSON K. L., SCHIFFMAN K. and DISIS M. L. (2001): Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest., 107, 477-484.
54. KNUTSON K. L., SCHIFFMAN K., CHEEVER M. A. and DISIS M. L. (2002): Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res., 8, 1014-1018.
55. KOLB H. J., SCHATTENBERG A., GOLDMAN J. M., HERTENSTEIN B., JACOBSEN N., ARCESE W., LJUNGMAN P., FERRANT A., VERDONCK L. and NIEDERWIESER D. (1995): Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 86, 2041-2050.
56. KUGLER A., STUHLER G., WALDEN P., ZOLLER G., ZOBYWALSKI A., BROSSART P., TREFZER U., ULLRICH S., MULLER C. A., BECKER V., GROSS A. J., HEMMERLEIN B., KANZ L., MULLER G. A. and RINGERT R. H. (2000): Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 6, 332-336.
57. LEE P., WANG F., KUNIYOSHI J., RUBIO V., STUGES T., GROSHEN S., GEE C., LAU R., JEFFERY G., MARGOLIN K., MARTY V. and WEBER J. (2001): Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol., 19, 3836-3847.
58. LOEB L. A. (1991): Mutator phenotype may be required for multistage carcinogenesis. Cancer Res., 51, 3075-3079.
59. LOEB L. A. (1996): Many mutations in cancers. Cancer Surv,. 28, 329-342.
60. LOPEZ R. D., XU S., GUO B., NEGRIN R. S. and WALLER E. K. (2000): CD2-mediated IL-12-dependent signals render human γδ-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood, 96, 3827-3837.
61. LUM L. G., LEFEVER A. V., TREISMAN J. S., GARLIE N. K. and HANSON J. P. JR. (2001): Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J. Immunother., 24, 408-419.
62. MEDZHITOV R. (2001): Toll-like receptors and innate immunity. Nat. Rev. Immunol., 1, 135-145.
63. MEDZHITOV R. and JANEWAY C. A. JR. (1997): Innate immunity: the virtues of a nonclonal system of recognition. Cell, 91, 295-298.
64. MITCHELL M. S. (1998): Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol., 25, 623-635.
65. MORSE M. A., DENG Y., COLEMAN D., HULL S., KITRELL-FISHER E., NAIR S., SCHLOM J., RYBACK M. E. and LYERLY H. K. (1999): A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res., 5, 1331-1338.
66. MORSE M. A., NAIR S. K., BOCZKOWSKI D., TYLER D., HURWITZ H. I., PROIA A., CLAY T. M., SCHLOM J., GILBOA E. and LYERLY H. K. (2002): The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int. J. Gastrointest. Cancer, 32, 1-6.
67. NORTH R. J. (1982): Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends upon elimination of tumor-induced suppressor T cells. J. Exp. Med., 155, 1063-1074.
68. NORTH R. J. (1984): Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother., 16, 175-181.
69. NOWELL P. C. (1976): The clonal evolution of tumor cell populations. Science, 194, 23-28.
70. OSSENDORP F., MENGEDE E., CAMPS M., FILIUS R. and MELIEF C. J. M. (1998): Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med., 187, 693-702.
71. PARMIANI G., CASTELLI C., DALERBA P., MORTARINI R., RIVOLTINI L., MARINCOLA F. M. and ANICHINI A. (2002): Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? JNCI Cancer Spectrum, 94, 805-818.
72. PLAUTZ G. E., BARNETT G. H., MILLER D. W., COHEN B. H., PRAYSON R. A., KRAUSS J. C., LUCIANO M., KANGISSER D. B. and SHU S. (1998): Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg., 89, 42-51.
73. PLAUTZ G. E., BUKOWSKI R. M., NOVICK A. C., KLEIN E. A., KURSH E. D., OLENCKI T. E., YETMAN R. J., PIENKNY A., SANDSTROM K. and SHU S. (1999): T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology, 54, 617-623.
74. PLAUTZ G. E., MILLER D. W., BARNETT G. H., STEVENS G. H., MAFFETT S., KIM J., COHEN P. A. and SHU S. (2000): T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res., 6, 2209-2218.
75. PORTER D. L., ROTH M. S., MCGARIGLE C., FERRARA J. L. and ANTIN J. H. (1994): Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med., 330, 100-106.
76. PREHN R. T. and MAIN J. M. (1957): Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst., 18, 769-778.
77. RAMARATHINAM L., SARMA S., MARIC M., ZHAO M., YANG G., CHEN L. and LIU Y. (1995): Multiple lineages of tumors express a common tumor antigen P1A, but they are not cross-protected. J. Immunol., 155, 5323-5329.
78. RENKVIST N., CASTELLI C., ROBBINS P. F. and PARMIANI G. (2001): A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother., 50, 3-15.
79. RESSING M. E., VAN DRIEL W. J., BRANDT R. M., KENTER G. G., DE JONG J. H., BAUKNECHT T., FLEUREN G. J., HOOGERHOUT P., OFFRINGA R., SETTE A., CELIS E., GREY H., TRIMBOS B. J., KAST W. M. and MELIEF C. J. (2000): Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother., 23, 255-266.
80. ROSENBERG S. A. (2001): Progress in human tumour immunology and immunotherapy. Nature, 411, 380-384.
81. ROSENBERG S. A., LOTZE M. T., YANG J. C., TOPALIAN S. L., CHANG A. E., SCHWARTZENTRUBER D. J., AEBERSOLD P., LEITMAN S., LINEHAN W. M. and SEIPP C. A. (1993): Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst., 85, 622-632.
82. ROSENBERG S. A., PACKARD B. S., AEBERSOLD P. M., SOLOMON D., TOPALIAN S. L., TOY S. T., SIMON P., LOTZE M. T., YANG J. C., SEIPP C. A., SIMPSON C., CARTER C., BOCK S., SCHWARTZENTRUBER D., WEI J. P. and WHITE M. S. (1988): Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Eng. J. Med., 319, 1675-1680.
83. ROSENBERG S. A., YANG J. C., SCHWARTZENTRUBER D. J., Hwu P., MARINCOLA F. M., TOPALIAN S. L., RESTIFO N. P., DUDLEY M. E., SCHWARTZ S. L., SPIESS P. J., WUNDERLICH J. R., PARKHURST M. R., KAWAKAMI Y., SEIPP C. A., EINHORN J. H. and WHITE D. E. (1998): Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4, 321-327.
84. ROSENBERG S. A., YANG Y. C., TOPALIAN S. L., SCHWARTENTRUBER D. J., WEBER J. S. and PARKINSON D. R. (1994): Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA, 271, 907-913.
85. ROSENBERG S. A., YANNELLI J. R., YANG J. C., TOPALIAN S. L., SCHWARTZENTRUBER D. J., WEBER J. S., PARKINSON D. R., SEIPP C. A., EINHORN J. H. and WHITE D. E. (1994): Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst., 86, 1159-1166.
86. SCHWARTZENTRUBER D. J., HOM S. S., DADMARZ R., WHITE D. E., YANNELLI J. R., STEINBERG S. M., ROSENBERG S. A. and TOPALIAN S. L. (1994): In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol., 12, 1475-1483.
87. SHU S., CHOU T. and ROSENBERG S. A. (1987): Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol., 139, 295-304.
88. SIMONS J. W., JAFFEE E. M., WEBER C. E., LIVITSKY H. I., NELSON W. G., CARDUCCI M. A., LAZENBY A. J., COHEN L. K., FINN C. C., CLIFT S. M., HAUDA K. M., BECK L. A., LEIFERMAN K. M., OWENS A. H. JR., PIANTADOSI S., DRANOFF G., MULLIGAN R. C., DARDOLL D. M. and MARSHALL F. F. (1997): Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57, 1537-1546.
89. SPIESS P. J., YANG J. C. and ROSENBERG S. A. (1987): In vivo antitumor activity: of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst., 79, 1067-1075.
90. STOLER D. L., CHEN N., BASIK M., KAHLENBERG M. S., RODRIGUEZ-BIGAS M. A., PETRELLI N. J. and ANDERSON G. R. (1999): The onset and extent of genomic instability in sporadic colorectal tumor progression [see comments]. Proc. Natl. Acad. Sci. USA, 96, 15121-15126.
91. + T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res., 62, 5041-5048.
92. THURNER B., HAENDLE I., RODER C., DIECKMANN D., KEIKAVOUSSI P., JONULEIT H., BENDER A., MACZEK C., SCHREINER D., VON DEN DRIESCH P., BROCKER E. B., STEINMAN R. M., ENK A., KAMPGEN E. and SCHULER G. (1999): Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med., 190, 1669-1678.
93. TO W. C., WOOD B. G., KRAUSS J. C., STROME M., ESCLAMADO R. M., LAVERTU P., DASKO D., KIM J. A., PLAUTZ G. E., LEFF B. E., SMITH V., SANDSTROM-WAKELING K. and SHU S. (2000): Systemic adoptive T cell immunotherapy in recurrent and metastatic carcinoma of the head and neck. Otolaryngology, 126, 1225-1231.
94. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91, 9461-9465.
95. TRAVERSARI C., VAN DER BRUGGEN P., LUESCHER I. F., LURQUIN C., CHOMEZ P., VAN PEL A., DE PLAEN E., AMAR-COSTESEC A. and BOON T. (1992): A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176, 1453-1457.
96. VAN DEN EYNDE B., LETHE B., VAN PEL A., DE PLAEN E. and BOON T. (1991): The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med., 173, 1373-1384.
97. VAN DER BRUGGEN P., TRAVERSARI C., CHOMEZ P., LURQUIN C., DE PLAEN E., VAN DEN EYNDE B., KNUTH A. and BOON T. (1991): A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647.
98. VISWANATHAN M., SANGILIYANDI G., VINOD S. S., MOHANPRASAD B. K. C. and SHANMUGAM G. (2003): Genomic instability and tumor-specific alterations in oral squamous cell carcinomas assessed by inter-(simple sequence repeat) PCR. Clin. Cancer Res., 9, 1057-1062.
99. VONDERHEIDE R. H., SCHULTZE J. L., ANDERSON K. S., MAECKER B., BUTLER M. O., XIA Z., KURODA M. J., BERGWELT-BAILDON M. S., BEDOR M. M., HOAR K. M., SCHNIPPER D. R., BROOKS M. W., LETVIN N. L., STEPHANS K. F., WUCHERPFENNIG K. W., HAHN W. C. and NADLER L. M. (2001): Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res., 61, 8366-8370.
100. WANG R.-F., WANG X., ATWOOD A. C., TOPALIAN S. L. and ROSENBERG S. A. (1999): Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science, 284, 1351-1354.
101. + T cells. J. Exp. Med., 189, 1659-1667.
102. WHITEHEAD R. P., LEW D., FLANIGAN R. C., WEISS G. R., ROY V., GLODE M. L., DAKHIL S. R. and CRAWFORD E. D. (2002): Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J. Immunother., 25, 352-358.
103. WHITEHEAD R. P., UNGER J. M., GOODWIN J. W., WALKER M. J., THOMPSON J. A., FLAHERTY L. E. and SONDAK V. K. (1998): Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group Study. J. Immunother., 21, 440-446.
104. WHITESIDE T. L., ZHAO Y., TSUKISHIRO T., ELDER E. M., GOODING W. and BAAR J. (2003): Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res., 9, 641-649.
105. YANNELLI J. R., HYATT C., MCCONNELL S., HINES K., JACKNIN L., PARKER L., SANDERS M. and ROSENBERG S. A. (1996): Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer, 65, 413-421.
106. YEE C. and GREENBERG P. (2002): Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat. Rev. Cancer, 2, 409-419.
107. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA, 99, 16168-16173.
108. YOSHIZAWA H., CHANG A. E. and SHU S. (1991): Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol., 147, 729-737.